208 related articles for article (PubMed ID: 29327109)
1. A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.
Ryan JM; Mittal P; Menoret A; Svedova J; Wasser JS; Adler AJ; Vella AT
Cancer Immunol Immunother; 2018 Apr; 67(4):605-613. PubMed ID: 29327109
[TBL] [Abstract][Full Text] [Related]
2. An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
Mittal P; Abblett R; Ryan JM; Hagymasi AT; Agyekum-Yamoah A; Svedova J; Reiner SL; St Rose MC; Hanley MP; Vella AT; Adler AJ
J Immunol; 2018 Feb; 200(4):1513-1526. PubMed ID: 29305435
[TBL] [Abstract][Full Text] [Related]
3. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.
Mittal P; St Rose MC; Wang X; Ryan JM; Wasser JS; Vella AT; Adler AJ
J Immunol; 2015 Dec; 195(12):5816-26. PubMed ID: 26561553
[TBL] [Abstract][Full Text] [Related]
5. A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors.
Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
Sci Rep; 2019 Jul; 9(1):10862. PubMed ID: 31350431
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
7. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.
Qui HZ; Hagymasi AT; Bandyopadhyay S; St Rose MC; Ramanarasimhaiah R; Ménoret A; Mittler RS; Gordon SM; Reiner SL; Vella AT; Adler AJ
J Immunol; 2011 Oct; 187(7):3555-64. PubMed ID: 21880986
[TBL] [Abstract][Full Text] [Related]
8. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
9. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
[TBL] [Abstract][Full Text] [Related]
10. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
[TBL] [Abstract][Full Text] [Related]
11. Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation.
Bandyopadhyay S; Long M; Qui HZ; Hagymasi AT; Slaiby AM; Mihalyo MA; Aguila HL; Mittler RS; Vella AT; Adler AJ
J Immunol; 2008 Dec; 181(11):7728-37. PubMed ID: 19017962
[TBL] [Abstract][Full Text] [Related]
12. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
[TBL] [Abstract][Full Text] [Related]
13. Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy.
Li W; Zhang X; Zhang C; Yan J; Hou X; Du S; Zeng C; Zhao W; Deng B; McComb DW; Zhang Y; Kang DD; Li J; Carson WE; Dong Y
Nat Commun; 2021 Dec; 12(1):7264. PubMed ID: 34907171
[TBL] [Abstract][Full Text] [Related]
14. Costimulation Endows Immunotherapeutic CD8 T Cells with IL-36 Responsiveness during Aerobic Glycolysis.
Tsurutani N; Mittal P; St Rose MC; Ngoi SM; Svedova J; Menoret A; Treadway FB; Laubenbacher R; Suárez-Ramírez JE; Cauley LS; Adler AJ; Vella AT
J Immunol; 2016 Jan; 196(1):124-34. PubMed ID: 26573834
[TBL] [Abstract][Full Text] [Related]
15. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
[TBL] [Abstract][Full Text] [Related]
16. Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
Ho SK; Xu Z; Thakur A; Fox M; Tan SS; DiGiammarino E; Zhou L; Sho M; Cairns B; Zhao V; Xiong M; Samayoa J; Forsyth CM; Powers DB; Chao DT; Hollenbaugh D; Alvarez HM; Akamatsu Y
Mol Cancer Ther; 2020 Apr; 19(4):1040-1051. PubMed ID: 31974274
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
18. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
[TBL] [Abstract][Full Text] [Related]
19. Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
Kotanides H; Sattler RM; Lebron MB; Carpenito C; Shen J; Li J; Surguladze D; Haidar JN; Burns C; Shen L; Inigo I; Pennello AL; Forest A; Chen X; Chin D; Sonyi A; Topper M; Boucher L; Sharma P; Zhang Y; Burtrum D; Novosiadly RD; Ludwig DL; Plowman GD; Kalos M
Mol Cancer Ther; 2020 Apr; 19(4):988-998. PubMed ID: 32241872
[TBL] [Abstract][Full Text] [Related]
20. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
